Andrew G Schneider

Address:

3701 Carnforth Dr, Columbus, OH 43221

VIN:

3VWEF71K17M163032

Make:

VOLKSWAGEN

Model:

JETTA

Year:

2007

US Patent:

6716963, Apr 6, 2004

Filed:

Nov 22, 1999

Appl. No.:

09/447226

Inventors:

Jack Henkin - Highland Park IL
Fortuna Haviv - Deerfield IL
Michael F. Bradley - Chicago IL
Douglas M. Kalvin - Buffalo Grove IL
Andrew J. Schneider - Gurnee IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07K 700

US Classification:

530328, 514 15

Abstract:

Peptides having the formula: wherein A is selected from hydrogen or an acyl group; A is a hydroxyl group or an amino acid amide; and A , A , A , A , A , A , A , A , and A are amino acyl residues as defined herein.

US Patent:

6753408, Jun 22, 2004

Filed:

Nov 22, 2000

Appl. No.:

09/718591

Inventors:

Fortuna Haviv - Deerfield IL 60015
Jack Henkin - Highland Park IL 60035
Michael F. Bradley - Chicago IL 60613
Douglas M. Kalvin - Buffalo Grove IL 60089
Andrew J. Schneider - Gurnee IL 60031

International Classification:

C07K 700

US Classification:

530328, 514 15

Abstract:

Peptides of formula (I) are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

US Patent:

6774211, Aug 10, 2004

Filed:

Apr 11, 2001

Appl. No.:

09/833196

Inventors:

Jack Henkin - Highland Park IL
Fortuna Haviv - Deerfield IL
Michael F. Bradley - Wadsworth IL
Douglas M. Kalvin - Buffalo Grove IL
Andrew J. Schneider - Gurnee IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07K 700

US Classification:

530328, 514 15

Abstract:

Peptides having the formula: wherein A is selected from hydrogen or an acyl group; A is a hydroxyl group or an amino acid amide; and A , A , A , A , A , A , A , A , and A are amino acyl residues as defined herein.

US Patent:

20020183242, Dec 5, 2002

Filed:

Apr 11, 2001

Appl. No.:

09/832733

Inventors:

Jack Henkin - Highland Park IL, US
Fortuna Haviv - Deerfield IL, US
Michael Bradley - Wadsworth IL, US
Douglas Kalvin - Buffalo Grove IL, US
Andrew Schneider - Gurnee IL, US

International Classification:

C07K017/00
C07K016/00
C07K014/00
C07K007/00
C07K005/00
C07K004/00
C07K002/00
A61K038/00
A01N037/18

US Classification:

514/002000, 530/300000

Abstract:

The present invention discloses peptides which are useful for inhibiting angiogenesis. Also disclosed are angiogenesis-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

US Patent:

20050124548, Jun 9, 2005

Filed:

Jan 23, 2004

Appl. No.:

10/764379

Inventors:

Jack Henkin - Highland Park IL, US
Fortuna Haviv - Deerfield IL, US
Michael Bradley - Chicago IL, US
Douglas Kalvin - Buffalo Grove IL, US
Andrew Schneider - Gurnee IL, US

International Classification:

A61K038/08
C07K007/06

US Classification:

514015000, 530328000

Abstract:

Peptides having the formula: A-A-A-A-A-A-A-A-A-A-A wherein Ais selected from hydrogen or an acyl group; Ais a hydroxyl group or an amino acid amide; and A, A, A, A, A, A, A, A, and Aare amino acyl residues as defined herein.

US Patent:

59325453, Aug 3, 1999

Filed:

Mar 16, 1998

Appl. No.:

9/039682

Inventors:

Jack Henkin - Highland Park IL
Noel P. Bouck - Oak Park IL
David W. Dawson - Chicago IL
Andrew J. Schneider - Gurnee IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 3800

US Classification:

514 13

Abstract:

Peptides having the formula: T-Gly-Val-D-Ile-Thr-Arg-Ile-U, V-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-W, X-D-Arg-D-Ile-D-Arg-D-Thr-lle-D-Val-Y, and Z-Gly-Val-Ile-Thr-Arg-Ile-U wherein T is absent or is selected from N-protecting group and a polypeptide of up to 12 amino acid residues optionally terminated with a N-protecting group; U is selected from Arg and Arg-NR. sup. 1 R. sup. 2 wherein R. sup. 1 and R. sup. 2 are independently selected from hydrogen and alkyl of one to four carbon atoms; V is absent or a N-protecting group; W is selected from D-Arg and D-Arg-NR. sup. 1 R. sup. 2 ; X is absent or a N-protecting group; Y is selected from Gly and Gly-NR. sup. 1 R. sup. 2 ; and Z is 1-12 amino acid residues optionally terminated with a N-protecting group wherein at least one of the amino acid residues is a D-amino acid residue inhibit angiogenesis and are useful in the treatment of disease states such as cancer, arthritis, macular degeneration and diabetic retinopathyin which angiogenesis plays a role.